Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Teza Capital Management LLC

Teza Capital Management LLC increased its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 47.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 99,818 shares of the company's stock after buying an additional 32,173 shares during the period. Teza Capital Management LLC's holdings in Elanco Animal Health were worth $1,209,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of ELAN. CoreCap Advisors LLC bought a new position in Elanco Animal Health in the fourth quarter worth approximately $29,000. Jones Financial Companies Lllp increased its position in shares of Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after purchasing an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. increased its position in shares of Elanco Animal Health by 221.2% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock worth $60,000 after purchasing an additional 3,411 shares in the last quarter. MRP Capital Investments LLC acquired a new position in shares of Elanco Animal Health during the fourth quarter worth $61,000. Finally, Blue Trust Inc. increased its position in shares of Elanco Animal Health by 47.7% during the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after purchasing an additional 1,894 shares in the last quarter. Institutional investors own 97.48% of the company's stock.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of the stock in a transaction on Tuesday, March 11th. The shares were bought at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the acquisition, the director now owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.89% of the stock is owned by corporate insiders.

Elanco Animal Health Stock Performance

Shares of ELAN traded down $0.01 during trading hours on Friday, reaching $12.66. 4,743,380 shares of the company traded hands, compared to its average volume of 5,073,930. The stock has a market capitalization of $6.29 billion, a P/E ratio of 31.66, a P/E/G ratio of 2.50 and a beta of 1.49. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $18.80. The business has a fifty day moving average price of $10.34 and a 200-day moving average price of $11.45.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the company earned $0.34 earnings per share. The firm's revenue was down 1.0% on a year-over-year basis. Equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Barclays reduced their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Morgan Stanley reduced their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. Piper Sandler reduced their price target on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Stifel Nicolaus boosted their price objective on shares of Elanco Animal Health from $15.00 to $16.00 and gave the company a "buy" rating in a report on Monday, May 19th. Finally, UBS Group dropped their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $15.17.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.